The management of coexisting depression in patients with dementia: Potential of calcium channel antagonists

Clinical Neuropharmacology

Volumn 20, Issue 1, 1997, Pages 22-35

  De Vry, Jean ^a   Fritze, Jürgen ^b   Post, Robert M ^c  

^a MEDA Manufacturing GmbH   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Calcium channel antagonists; Dementia; Depression; Nimodipine

Indexed keywords

CALCIUM ANTAGONIST; DILTIAZEM; NIFEDIPINE; NIMODIPINE; SEROTONIN UPTAKE INHIBITOR; VERAPAMIL;

AGED; ARTICLE; COGNITION; DEMENTIA; DEPRESSION; DISEASE ASSOCIATION; DRUG EFFECT; DRUG TOLERABILITY; HUMAN; NEUROTRANSMITTER RELEASE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; WELLBEING;

EID: 0031020580     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199702000-00003     Document Type: Article

References (88)

1. American Psychiatric Association. Diagnostic and statistical manual. 3rd rev. Washington, D.C.: American Psychiatric Association, 1987.
2. Wragg RE, Jeste DV. Overview of depression and psychosis in Alzheimer's disease. Am J Psychiatry 1989;146:577-87.
3. Cummings JL, Victoroff JI. Non-cognitive neuropsychiatric syndromes in Alzheimer's disease, Neuropsychiatry Neuropsychology Behav Neurol 1990;3:140-58.
4. Förstl H, Burns A, Luthert P, Cairns N, Lantos P, Levy R. Clinical and neuropathological correlates of depression in Alzheimer's disease. Psychol Med 1992;22:877-84.
5. Reifler BV, Larson E, Teri L, Poulsen M. Dementia of the Alzheimer's type and depression. J Am Geriatr Soc 1986;34:855-9.
6. Keegan D, Bowen RC, Blackshaw S, et al. A comparison of fluoxetine and amitriptyline in the treatment of major depression. Int Clin Psychopharmacol 1991;6:117-24.
7. Cummings JL, Ross W, Absher J, Gombein J, Hadjiaghai L. Depressive symptoms in Alzheimer disease: assessment and determinants. Alzheimer Dis Assoc Disord 1995;9:87-93.
8. Burke W, Rubin E, Morrris J, Berg L. Symptoms of "depression" in dementia of the Alzheimer's type. Alzheimer Dis Assoc Disord 1988;2:356-62.
9. Salzman C. Geriatric psychopharmacology. Annu Rev Med 1985;36:217-28.
10. Baldwin RC. Is there a distinct subtype of major depression in the elderly? J Psychopharmacl 1994;8:177-84.
11. Ancill RJ. What's treatable in dementia? The treatment of depression in dementia. Clin Neuropharmacol 1990;13(suppl 2):14-1-1.
12. Grof P, Angst J, Haines T. The clinical course of depression: practical issues. In: Angst J, ed. Classification and prediction of outcome of depression. Stuttgart: FK Schattauer Verlag, 1974:141-8.(Symposia Medica Hoechst: vol 8).
13. Román GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-60.
14. Förstl H, Levy R, Burns A, Luthert P, Cairns N Disproportionate loss of noradrenergic, and cholinergic neurons as cause of depression in Alzheimer's disease - a hypothesis. Pharmacopsychiatry 1994;27:11-5.
15. Bierer LM, Haroutunian V, Gabriel S, et al. Neurochemical correlates of dementia severity in Alzheimer's disease, relative importance ot the cholinergic deficits. J Neurochem 1995;64:749-60.
16. Davis KL, Davidson M, Yang RK, et al. CSF somatostatin in Alzheimer's disease, depressed patients, and control subjects. Biol Psychiatry 1988;24:710-2.
17. Soininen H, Riekkinen PJ, Partanen J, et al. Cerebrospinal fluid somatostatin correlates with spectral EEG variables and with parietotemporal cognitive dysfunction in Alzheimer patients. Neurosci Lett 1988;85:131-6.
18. Serby M, Richardson SB, Twente S, Siekierski J, Corwin J, Rotrosen J. CSF somatostatin in Alzheimer's disease. Neurobiol Aging 1984;5:187-9.
19. Wood PL, Etienne P, Lal S, Gauthier S, Cajal S, Nair NP. Reduced lumbar CSF somatostatin levels in Alzheimer's disease. Life Sci 1982:31-2073-9.
20. Rubinow DR. Cerebrospinal fluid somatostatin and psychiatric illness. Biol Psychiatry 1986;21:341-65.
21. Rubinow DR, Davis CL, Post RM. Somatostatin in neuropsychiatric disorders. In: Weill C et al. eds. Basic and clinical aspects of neuroscience. Berlin: Springer-Verlag, 1992:29-42.
22. Vecsei L, Bollok I, Telegdy G. Intracerebroventricular somatostaim attenuates electroconvulsive shock-induced amnesia in rats. Peptides 1983;4:293-5.
23. DeNoble VJ, Hepler DJ, Barto RA. Cysteamine-induced depletion of somatostatin produces differential cognitive deficits in rats. Brain Res 1989;482:42-8.
24. Vecsei L, Kiraly C, Bollok I, et al. Comparative studies with somatostatin and cysteamine in different behavioural tests on rats. Pharmacol Biochem Behav 1984;21:833-7.
25. Schettini G, Florio T, Magri G, et al. Somatostatin and SMS 201-995 reverse the impairment of cognitive functions induced by cysteamine depletion of brain somatostatine. Eur J Pharmacol 1988;151:399-407.
26. Pazzaglia PJ, George MS, Post RM, Rubinow DR, Davis C. Nimodipine increases CSF somatostatin in affectively ill patients. Neuropsychopharmacology 1995;13:75-83.
27. Salzman C. Treatment of agitation, anxiety and depression in dementia. Psychopharmacol Bull 1988;24:39-42.
28. Jenike MA. Monoamine oxidase inhibitors as treatment for depressed patients with primary degenerative dementia (Alzheimer's disease). Am J Psychiatry 1985;142:763-4.
29. Reifler BV, Teri L, Raskind M, et al. Double-blind trial of imipramine in Alzheimer's disease patients with and without depression. Am J Psychiatry 1989;146:45-9.
30. Harris MH, Gierz M, Lohr JB. Recognition and treatment of depression in Alzheimer's disease. Geriatrics 1989;44:26-30.
31. Ohara K. Depression in the elderly. Nippon Ronen Igakkai Zasshi 1995; 32:9-14.
32. Casey DA. Depression in the elderly. South Med J 1994;87:559-63.
33. Colenda CC. Drug treatment of behaviour problems in eldely patients with dementia: part 1. Drug Ther 1991:15-20.
34. Dose M. Psychopharmacology of affective disorders: is there a common denominator? [Abstract]. Curr Aspects Clin Psychopharmacol 1991; Abstract book:12a.
35. Volz H-P, Moller H-J. Antidepressant drug therapy in the elderly - a critical review of the controlled clinical trials conducted since 1980. Pharmacopsychiatry 1994;27:93-100.
36. Peselow ED, Corwin J, Fieve RR, Rotrosen J,Cooper TB. Disappearance of memory deficits in outpatient depressives responding to imipramine. J Affect Disord 1991;21:173-83.
37. Pathy MSJ. What's treatable in dementia? The pharmacological management of cognitive impairment in the demented patient. Clin Neuropharmacol 1990;13 (suppl 2):14-1-4.
38. Branconnier RJ, Cole JO, Ghazvinian S, Rosenthal S. Treating the depressed elderly patient: the comparative behavioural pharmacology of mianserin and amitriptyline. In: Costa E, Racagni G, eds. Typical and atypical antidepressants: clinical practice. New York: Raven Press, 1982:195-212.
39. de Rekeneire N, Kuntzmann F. Spécificité de la psythopharmacologie chez le sujet age. Psychol Med 1994;5:460-4.
40. Leibovici A, Tariot PN. Agitation associated with dementia: a systematic approach to treatment. Psychopharmacology 1988;24:49-53.
41. Risse SC, Barnes R. Pharmacologic treatment of agitation associated with dementia. J Am Geriatr Soc 1986;34:368-76.
42. Nomikos GG, Damsma G, Wenkstern D, Fibiger HC. Effects of chronic bupropion on interstitial concentrations of dopamine in rat nucleus accumbens and striatum. Neuropsychopharmacology 1992;7:7-14.
43. Nomikos GG, Damsma G, Wenkstern D, Fibiger HC. Acute effects of bupropion on extracellular dopamine concentrations in rat striatum and nucleus accumbens studied by in vivo microdialysis. Neuropsychopharmacology 1989;2:273-9.
44. Pucilowski O. Psychopharmacological properties of calcium channel inhibitors. Psychopharmacology 1992; 109:12-29.
45. Dubovsky SL, Murphy J, Christiano J, Lee C. The calcium second messenger system in bipolar disorders: data supporting new research directions. J Neuropsychiatry 1992;4:3-14.
46. Dubovsky SL, Thomas M, Hijazi A, Murphy J. Intracellular calcium signalling in peripheral cells of patients with bipolar affective disorder. Eur Arch Psychiatry Clin Neurosci 1994;243:229-34.
47. Dubovsky SL, Murphy J, Thomas M, Rademacher J. Abnormal intracellular calcium ion concentration in platelets and lymphocytes of bipolar patients. Am J Psychiatry 1992;149:118-20.
48. Dubovsky SL. Editorial - why don't we hear more about the calcium antagonists? Biol Psychiatry 1994; 35:149-50.
49. Eckert A, Gann H, Riemann D, Aldenhoff J, Muller WE. Platelet and lymphocyte-free intracellular calcium in affective disorders. Eur Arch Psychiatry Clin Neurosci 1994;243:235-9.
50. Traber J, van der Staay FJ, De Vry J. Nimodipine and nervous system function. In Busse WD, Garthoff B, Seuter F, eds. Dihydropyridines: progress in pharmacology and therapy. Berlin: Springer - Verlag, 1993:71-80.
51. Höschl C. Do calcium antagonists have a place in the treatment of mood disorders? Drugs 1991;42:721-9.
52. Van den Kerckhoff W, Drewes LR. Transfer of nimodipine and another calcium antagonist across the blood-brain barrier and their regional distribution in vivo. In. Bergener M, Reisberg B, eds. Diagnosis and treatment of senile dementia. Berlin: Springer. 1989:308-21.
53. De Vry J, de Beun R. Behavioural profile of the calcium channel blocker nimodipine in animal models of alcoholism and depression. Neuropsychopharmacology 1994;10:231S.
54. Belleman P, Schade A, Towart R. Dihydropyridine receptor in rat brain labeled with (3H)nimodipine. Proc Natl Acad Sci USA 1983;80:2356-60.
55. Mogilnicka E, Czyrak A, Maj J. Dihydropyridine calcium channel antagonists reduce immobility in the mouse behavioural despair test; antidepressants facilitate nifedipine action. Eur J Phamacol 1987;138:413-6.
56. Eccleston D, Cole AJ. Calcium-channel blockade and depressive illness. Br J Psychiatry 1990;156:889-91.
57. A receptors in depression and anxiety. New York: Raven Press, 1992:55-81.
58. Czyrak A, Mogilnicka E, Maj J. Dihydropyridine calcium channel antagonists as antidepressant drugs in mice and rats. Neuropharmacology 1989;28:229-33.
59. De Vry J, Eckel G, Jentzsch KR. Effects of the calcium channel blocker nimodipine in animal models of depression. Proceedings of the 2nd International Conference on New Directions in Affective Disorders. Jerusalem, 1995, abstract P-12.
60. Mogilnicka E,Czyrak A, Maj J. BAY K8644 enhances immobility in the mouse behavioral despair test, an effect blocked by nifedipine. Eur J Pharmacol 1988;151:307-11.
61. Srivastava SK, Nath C, Gupta GP, Dhawan KN. Differential effects of calcium channel blockers on behavioural depression in mice. J Psychopharmacol 1992;6:118.
62. Czyrak A, Mogilnicka E, Siwanowicz J, Maj J. Some behavioral effects of repeated administration of calcium channel antagonists. Pharmacol Biochem Behav 1990;35:557-60.
63. Tazi A, Farh M, Moumni M, Hakkou F. Potentiation of behavioural effects of a calcium channel antagonist, nifedipine, by ipsapirone. Behav Pharmacol 1992;3:269-73.
64. Kostowski W, Dyr W, Pucilowski O. Activity of diltiazam and nifedipine in some animal models of depression. Pol J Pharmacol Pharm 1990;42:121-7.
65. Eroglu L, Esin Y. Effects of long-term nifedipine treatment in rats. Psychiatry Res 1990;32:203-5.
66. Czvrak A. Effcet of chronic nifedipine and ECT in the forced swimming test in rats. Pol J Pharmacol Pharm 1993;45:191-5.
67. Czyrak A. The effect of antidepressant drugs and nifedipine in the forced swimming test in rats. Eur Neuropsychopharmacol 1993;3:345-6.
68. Bidzinski A, Jankowska E, Pucilowski O. Antidepressant-like action of nicardipine, verapamil and hemicolinium-3 injected into the anterior hypothalamus in the rat forced swim test. Pharmacol Biochem Behav 1990;36:795-8.
69. Kozlovskii VL, Prakhé IV. Calcium channel blockers as antidepressants: a property of the class or of the individual preparation.' Eksp Klini Farmakol 1994;57:17-20.
70. Martin P, Laurent S, Massol J, Childs M, Puech AJ. Effects of dihydropyridine drugs on reversal by imipramine of helpless behavior in rats. Eur J Pharmacol 1989;162:185-8.
71. 2+ antagonists in the CNS. Branford: Neva Press, 1993:165-74.
72. Geoffroy M, Mogilnicka E, Nielsen M, Rafaelsen OJ. Effect of nifedipine on the shuttlebox escape deficit induced by inescapable shock in the rat. Eur J Pharmacol 1988;154:277-83.
73. Ossowska G, Klenk-Majewska B. The effects of calcium channel antagonists on the aggressive behavior in chronically stressed rats. Pol J Pharmacol Pharm 1992;44:197.
74. Fundaro A. Behavioural effects of chronic administration of nimodipine in grouped or individually housed rats. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:299-312.
75. Nowak G, Paul IA, Popik P, Young A, Skolnick P. Calcium antagonist effects on antidepressant-like adaptation of the NMDA receptor complex. Eur J Pharmacol 1993;247:101-2.
76. Brunet G, Cerlich B, Robert P, Dumas S, Souetre E, Darcourt G. Open trial of a calcium antagonist, nimodipin, in acute mania. Clin Neuropharma col 1990;13:224-8.
77. Dubovsky SL. Calcium antagonists in manic-depressive illnesses. Neuropsychobiology 1993;27:184-92.
78. Höschl C, Kozeny J. Verapamil in affective disorders: a double-blind, controlled study. Biol Psychiatry 1989;25:128-40.
79. Pazzaglia PJ, Post RM, Ketter TA, George MS, Marangell LB. Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. Psychiatry Res 1993;49:257-72.
80. Fritze J, Walden J. Clinical findings and nimodipine in dementia: test of the calcium hypothesis. J Neural Transm 1995;46(suppl.):439-53.
81. Walden J, Fritze J, van Calker D, Berger M, Grunze H. A calcium antagonist for the treatment of depressive episodes: single case reports. J Psychiatr Res 1995;29:71-6.
82. Manna V. Bipolar affective disorder and intraneural calcium. Treatment with lithium salts and/or calcium antagonist in patients with rapid polar inversion of mood tone. Minerva Med 1991;82:757-63.
83. Grunae H, Walden J, Wolf R, Berger M. Combined treatment with lithium and nimodipine in a bipolar II manic syndrome. Neuropsychopharmacology 1994;10:135S.
84. Ban TA, Morey L, Aguglia E, et al. Nimodipine in the treatment of old age dementias. Prog Neuropharmacol Biol Psychiatry 1990;14:525-51.
85. Eckmann F. Clinical studies on nimodipine in the treatment of patients with depressive syndromes in the second half of life. In: Betz E, Deck K, Hoffmeister F, eds. Nimodipine: pharmacological and clinical studies. Stuttgart: Schattauer, 1985:307-13.
86. Montenegro R, Cornide E, Castro JM. Nimodipine in the treatment of involutional depressive syndrome. In: Betz E, Deck K, Hoffmeister F, eds. Nimodipine: pharmacological and clinical studies. Stuttgart: Schattauer, 1985:307-13.
87. Walden J, Grunze H, Hellhammer D, Fritze J, Berger M. Treatment of depressive episodes with the calcium antagonist nimodipine: single case reports (Abstract). Neuropsychopharmacology 1994;10:233S.
88. Canade V, Catapano F, Muraca L, Cosentino A. Effects of nimodipine on menial deterioration in subjects with chronic cerebrovascular pathology. Minerva Med 1991;82:111-4.